How much is a pharmacy worth? Mostly what its goodwill is worth. In most businesses goodwill is whatever's left over once the assets are counted; in a pharmacy it's the deal itself, so it's the number buyer and seller spend their time arguing about. Know what drives it and how a valuation is built, and you negotiate from knowledge rather than guesswork.
There are two ways to value it, and a handful of things that move the number. You won't get a headline multiple from us, and you shouldn't take one from anyone who hasn't seen your figures. And if you're buying through a company, there's a corporation tax trap to check before heads of terms.
The short answer: goodwill is most of the price, and the NHS contract is the reason
In a community pharmacy sale, goodwill is the dominant asset. The dispensing counter, the shopfit and the stock are worth relatively little on their own. What buyers are paying for is the right to operate the NHS community pharmacy contract from that location, and the income stream that flows from it.
That income is contract-driven, not till-driven. The Drug Tariff sets the reimbursement price; the CPCF sets the remuneration fees. A pharmacy with a high, stable dispensing volume and a service-income line (such as Pharmacy First) is a reliable income stream with high barriers to entry. That reliability is what buyers price as goodwill.
Item volume is the proxy for that reliability you can actually see. A higher monthly item count signals a larger, more established patient base and a more deeply embedded local contract. That's why goodwill gets talked about in items as well as earnings, why a pharmacy sale listing leads with items per month, and why both method families anchor to it in different ways.
Want this checked against your specific situation?
Leave your details and a one-line summary. One of our specialists will come back to you, with no obligation.
What goodwill actually is in a pharmacy sale
In accounting terms, goodwill is what you pay over the fair value of the identifiable net assets. In a pharmacy, goodwill dominates the price, so those net assets (equipment, stock, any property) are the smaller part of it. What's left is goodwill.
In practice, pharmacy goodwill bundles together several things that cannot be easily separated:
- The NHS contract itself. Market entry is regulated under the NHS (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013. You cannot simply open a new pharmacy wherever you like; the contract is the scarce asset. Whoever buys gets the right to operate from that location under that contract.
- The dispensing income stream. A well-established dispensing volume signals long-standing patient loyalty and GP referral relationships. That income does not disappear when ownership changes (subject to the transition being well managed).
- Service income lines. Pharmacy First and similar advanced services are a separately accounted revenue line: in 2026/27 each Pharmacy First clinical pathway consultation pays £17, with fixed monthly payments of £500 at 20 to 29 consultations and £1,000 at 30 or more. A pharmacy with strong service income has a second income stream beside dispensing to put in front of a buyer.
- Customer base and location. Proximity to GP surgeries, nursing homes, or residential density all feed into future volume expectations.
Goodwill can pass to a buyer, but only through the regulatory steps. The NHS contract changes hands under the 2013 Regulations, and the GPhC register entry for the premises is only made for someone lawfully running the pharmacy business there (Medicines Act 1968 s74B). Follow them and the goodwill transfers, and that's what makes it a bankable asset and a financeable purchase.
Method family 1: a multiple of adjusted EBITDA
The first method applies a market-derived multiple to the pharmacy's adjusted EBITDA: earnings before interest, tax, depreciation and amortisation, with certain add-backs applied.
What "adjusted" means. Raw EBITDA from the accounts can include costs that are specific to the current owner and wouldn't transfer to a buyer. The adjustments to look for:
- Owner's salary or drawings above (or below) a market-rate pharmacist salary. The valuation should reflect what the business earns after paying a replacement superintendent pharmacist at market rate.
- Personal expenses run through the business that would not continue under new ownership.
- Non-recurring costs or one-off income that inflates or deflates a single year's earnings.
- Rent at a non-arm's length figure (for example where the owner also owns the freehold).
So adjusted EBITDA is what the business earns for any competent owner, with the current one's circumstances stripped out. It's the number a buyer will pay a multiple of, and the one financial due diligence rebuilds from the accounts.
When this method is most useful. It suits a pharmacy with a meaningful service income line, because service income flows through EBITDA in a way a pure dispensing-volume metric doesn't capture. It also suits a larger pharmacy whose earnings are solid enough for a lender to lend against.
Method family 2: pence-per-item benchmarks
The second method family values the pharmacy by applying a benchmark price (expressed in pence) to each dispensing item dispensed per year. A pharmacy dispensing a higher volume of items will produce a higher raw goodwill figure under this approach.
What it measures. The pence-per-item approach essentially prices the dispensing throughput directly, treating each item as a unit of contracted income rather than trying to model profitability. It's a volume-anchored method, and its appeal is that item volume is transparent, auditable and hard to manipulate.
Its limitation. Two pharmacies dispensing the same number of items can have very different profitability if their service income, margin profile, staffing costs and overheads differ. A high-volume pharmacy with a compressed margin and heavy Category M exposure (DHSC resets those Drug Tariff prices each quarter, and the clawback recoups past over-delivery through lower prices later) may look attractive on items but less so on earnings. A buyer and their adviser will cross-check item volume against the earnings picture before accepting a pence-per-item price at face value.
When this method is most useful. As a cross-check alongside adjusted EBITDA, or as the main lens for a smaller pharmacy that's mostly dispensing, where owner arrangements can distort the earnings figure.
Why this post does not quote a multiple or a pence-per-item figure
You'll find headline multiples and "the market is typically X times" lines online. Before you lean on one, check it carries a named source, a date and the type of pharmacy it applies to. Both the multiple and the pence-per-item rate move with transaction volumes, the finance available, competition for a location and the income mix. A figure from two years ago, taken from a 30,000-item rural pharmacy, says almost nothing about the price of a 60,000-item urban one today. Lean on it and a seller can undersell, or a buyer can overpay for a business whose margin is already squeezed.
The honest answer: the methods exist (adjusted EBITDA multiple; pence-per-item), they're both legitimate, and the right number needs:
- Current transaction data from a specialist pharmacy broker who has completed comparable deals recently.
- Your specific financials, adjusted correctly.
- An informed view on the drivers covered in the next section.
The accountant's job is to build the adjusted EBITDA correctly, make sure the add-backs stand up, and have the tax on the agreed price understood before heads of terms. The current market view on multiples comes from a broker with live deals. Our pharmacy valuation and goodwill service covers the accounting side, and we can refer you to a specialist pharmacy broker for the market view.
What moves your valuation up or down
Within any given method, the output is not mechanical. The following drivers move the adjusted EBITDA figure, the pence-per-item benchmark applied, or both.
| Driver | Direction | Why it matters |
|---|---|---|
| Dispensing item volume | Higher volume, higher value | More items signal a larger, more embedded patient base and more contracted income. The NHS contract is the asset; volume is the evidence of its depth. |
| Service income (including Pharmacy First) | Strong service income lifts value | Service income is a separately accounted line with its own fee structure. A pharmacy already earning well from advanced services shows clinical engagement and has income beyond dispensing to point to. |
| Margin story and Category M exposure | Opaque or volatile margins discount value | Where a large share of dispensing is Category M drugs, the gross margin moves with the prices DHSC sets each quarter. A buyer can't rely on that margin holding, which increases risk and may reduce the multiple applied to EBITDA. |
| Lease terms | Long, assignable lease adds value; short or conditional lease discounts it | A buyer needs security of tenure to operate the contract and recoup the goodwill price. A short unexpired term, or onerous alienation clauses, introduces risk that reduces what a buyer will pay. |
| Owner dependency | High dependency discounts value | Where dispensing income or key GP relationships depend on the current owner-pharmacist being present, a buyer faces transition risk. A pharmacy with a stable employed superintendent pharmacist or a self-running team is more transferable. |
| Contract type and history | Clean, unencumbered contracts at full value | Contracts that are under review, subject to conditions or recently relocated carry regulatory risk. Buyers and their solicitors will examine the contract history under the 2013 Regulations before completing. |
They stack. High volume, strong service income, a clear margin, a long lease and a team that runs without the owner: that pharmacy negotiates from strength. Volume with a short lease, an opaque margin and an owner who is the business, and buyers price in the risk.
The structuring footnote: goodwill and corporation tax relief on a company purchase
If you're buying through a company, there's a tax position to check before you agree the price, and it turns on what comes with the goodwill.
On a company purchase, corporation tax relief on goodwill is restricted and only available in limited cases at fixed rates. When a company buys the business on or after 1 April 2019, relief at a fixed 6.5% a year depends on it also acquiring qualifying IP assets, and is capped at six times what the IP cost; without them there's no relief while it owns the goodwill (CTA 2009 s879I). The statute's list of qualifying IP is narrow (CTA 2009 s879J: patents, registered designs, copyright and design rights, plant breeders' rights and licences of them), and if the company later sells the goodwill at a loss, that loss counts only as a non-trading debit.
So if you're paying a large sum for goodwill and expecting to write it off against corporation tax over the years, you may get nothing while the company owns it, and the real cost of the purchase is higher than the price suggests.
That's one reason share or asset is the first structuring question. A share deal inherits the company's history and pays 0.5% stamp duty on the shares (until late 2027, when the announced Securities Transfer Tax is due to take over); an asset deal pays SDLT on any property at non-residential rates up to 5%, and on a new lease's rent, but starts clean, and where a company buys, the goodwill relief follows the IP rule above. The trade-offs are worked through in share versus asset purchase for pharmacies.
Getting a proper valuation view
If you are considering a sale or are at an early stage of valuing a pharmacy for purchase, the practical path is:
- Get your adjusted EBITDA figure right. This means working with an accountant who understands pharmacy-specific adjustments: market-rate superintendent salary, Category M margin normalisation, owner expenses, and any non-recurring items. Get it wrong and every valuation built on it is wrong too.
- Understand your item volume and its trend. A growing item count over three years tells a different story to a flat or declining one, even if the current volume is the same.
- Commission a specialist pharmacy broker view. A broker with live pharmacy transaction data can give you a current market range for your business type, location and earnings profile. That range, applied to your adjusted EBITDA or item volume, is the closest thing to a reliable indication of value.
- Review the tax position before heads of terms. Buying or selling, get the tax on the structure (BADR, goodwill relief, SDLT or stamp duty) clear before a price is agreed, not after.
Our pharmacy valuation and goodwill service covers the accounting side: building the adjusted EBITDA, testing a seller's figures and the tax for both sides. Once a price is in range, the pharmacy purchase affordability calculator works through the purchase arithmetic (it doesn't value the pharmacy or assume a multiple). Thinking of selling? Start with the selling a pharmacy hub. Buying? The buying a pharmacy hub covers the whole process.
The NHS contract figures here are England's. Scotland, Wales and Northern Ireland have devolved NHS contract arrangements; the valuation principles carry across, but check the contract specifics there.